Join us in this episode of the Oncology Brothers podcast as we dive deep into the rapidly evolving treatment landscape for small-cell lung cancer. Hosted by community oncologists Drs. Rahul and Rohit Gosain, we are thrilled to welcome Dr. Ticiana Leal, a thoracic medical oncologist from the Winship Cancer Institute - Emory University.

In this episode, we covered:

•⁠  ⁠We covered the recent approval of durvalumab in limited stage setting post chemoRT.

•⁠  We touched on the role of growth factors, and how they get rarely utilized, and covered use of Trilaciclib.

•⁠ Stressed the importance of immunotherapy in extensive stage with choices of Atezolizumab and Durvalumab, and touched on extended survival data with Atezolizumab

•⁠  Talked about logistical issues and uptake of Tarlatamab post approval.

Whether you're a practicing oncologist or simply interested in the latest advancements in cancer treatment, this episode is packed with valuable information to help guide your practice.

Follow us on social media:

Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!

Join us in this episode of the Oncology Brothers podcast as we dive deep into the rapidly evolving treatment landscape for metastatic non-small cell lung cancer (NSCLC) with actionable mutations in frontline therapy. Hosted by community oncologists Drs. Rahul and Rohit Gosain, we are thrilled to welcome Dr. Susan Scott, a thoracic medical oncologist from the Johns Hopkins Hospital.

In this episode, we covered:

Whether you're a practicing oncologist or simply interested in the latest advancements in cancer treatment, this episode is packed with valuable information to help guide your practice.

YouTube: https://youtu.be/LMYDAjZcn5w

Follow us on social media:

Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!

Welcome to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Mark Awad, a world-renowned thoracic medical oncologist from Memorial Sloan Kettering. Together, they dived deep into the treatment landscape for metastatic non-small cell lung cancer (NSCLC) without actionable mutations in frontline settings.

Episode Highlights:

Join us as we explored the complexities of treating metastatic NSCLC and the ongoing need for clinical trials and biomarker discovery. Don't forget to check out our other episodes for more insights on treatment algorithms and recent FDA approvals!

Follow us on social media:

Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!

In this episode of the Oncology Brothers podcast, Drs. Rahul & Rohit Gosain wrap up their three-part CME series on HER2-positive biliary tract cancer. Joined by Dr. Rachna Shroff, they delved into the critical topic of managing adverse events associated with treatments like TDXD and Zanidatamab.

The discussion covered:

Tune in to gain valuable insights on how to improve patient quality of life while navigating the complexities of HER2-positive biliary tract cancer treatments.

Follow us on social media:

Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!

Welcome to another episode of the Oncology Brothers podcast! In this episode, we dived into the recent FDA approval of Durvalumab combined with chemotherapy for resectable muscle-invasive bladder cancer, based on the NIAGARA trial.

Join us as we chat with Dr. Thomas Powles, a GU medical oncologist and the lead author of the NIAGARA trial. We discussed the study design, the significant improvements in overall survival, and the implications of this new treatment approach. Dr. Powles shared insights on the use of immunotherapy in the perioperative setting, the importance of pathological complete response, and the safety of combining Durvalumab with chemotherapy.

Key topics covered in this episode:

YouTube: https://youtu.be/s_tXoX5yhV8

Follow us on social media:

Tune in to learn how these advancements are changing the landscape of bladder cancer treatment and improving patient outcomes. Don't forget to like, subscribe, and check out our other episodes for more insights on oncology and FDA approvals!

Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rohit and Rahul Gosain, both practicing community medical oncologists, continue their discussion on HER2-positive biliary tract cancer. They are joined by Dr. Shubham Pant from MD Anderson, who shares his expertise on this rapidly evolving field.

In this episode, we cover:

Join us as we delve into the latest data and strategies for managing HER2-positive biliary tract cancer, and stay tuned for our next episode where we will discuss side effects and management of these therapies.

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

Link to gain CME credits from this activity:

Follow us on social media:

Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!

This is the second episode of a two-part series on the HER2 diagnostic and treatment landscape in non-small cell lung cancer (NSCLC), hosted by the Oncology Brothers, Drs Rohit and Rahul Gosain.   

Follow us on social media:

Don't forget to subscribe for the next episode

Welcome to the Oncology Brothers podcast! In this episode, Drs. Rohit and Rahul Gosain are joined by Dr. Ghassan Abou-Alfa, a medical oncologist specializing in the hepatobiliary space at Memorial Sloan Kettering. Together, they explored the current treatment landscape of biliary tract cancer, focusing on the advancements in HER2-driven therapies.

Key topics discussed included:

• The evolution of treatment options for biliary tract cancer, including chemotherapy and immunotherapy.

• The significance of genetic testing, including IDH1 mutations, FGFR alterations, and HER2 status.

• The role of multidisciplinary collaboration in managing hepatobiliary cancers.

• Insights into the latest clinical trials and emerging therapies for HER2-positive biliary tract cancer.

Join us as we delve into the complexities of biliary tract cancer and the promising developments in HER2-targeted treatments. Don't forget to check out our next episode, where we will take a deeper dive into the data surrounding HER2 therapies and discuss management strategies for common side effects.

YouTube: https://youtu.be/pGiU7JJGNOc

Follow us on social media:

•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers

•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers

•⁠  Website: https://oncbrothers.com/

Subscribe to stay updated on the latest in oncology!

#OncologyBrothers #BiliaryTractCancer #HER2 #CancerTreatment #MedicalOncology #CME #Podcast

Join us for an insightful episode of the Oncology Brothers podcast as we dive into the fast-evolving landscape of HER2-positive non-small cell lung cancer (NSCLC). In this first part of the two-part series, Drs. Rahul and Rohit Gosain were joined by Dr. Devika Das, a thoracic medical oncologist, and Dr. Fernando Lopez-Rios, a pathologist, to discuss the critical importance of testing and identifying HER2 alterations in lung cancer patients.

In this episode, we covered:

Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode provides valuable information on the integration of precision medicine in lung cancer treatment.

YouTube: https://youtu.be/gMi-sflQyQo

Follow us on social media:

Don't forget to subscribe for the next episode, where we will explore treatment options for HER2-positive non-small cell lung cancer in greater detail!

Welcome back to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Joshua Sabari, a thoracic medical oncologist from NYU, to discuss the latest findings from the European Lung Cancer Conference (ELCC) 2025.

We dived into several key studies that are shaping the future of lung cancer treatment, including:

Join us as we discuss the implications of these studies, the importance of next-generation sequencing (NGS), and how to manage side effects associated with these new therapies.

YouTube: https://youtu.be/akoXXAUEl_8

Follow us on social media:

Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in oncology!

#Oncology #LungCancer #ELCC2025 #EGFR #KRAS #CancerResearch #Podcast